Lv6
1740 积分 2021-11-26 加入
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
1个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1个月前
已完结
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
2个月前
已完结
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
3个月前
已完结
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
3个月前
已完结
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
3个月前
已完结
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
